Company Insights

LSTA customer relationships

Explore interactive graphBrowse insights index
LSTA customer relationship map

Lisata Therapeutics (LSTA): Partner map, revenue levers and what the customer relationships reveal

Lisata Therapeutics operates as a small clinical-stage biotech that develops and monetizes a proprietary iRGD cyclic peptide, certepetide, primarily through licensing and supply agreements rather than direct commercial sales. Revenue to date has come from upfront license payments and supply commitments, with value capture dependent on milestone triggers, reagent supply contracts, and recently negotiated acquisition economics. For investors evaluating counterparty exposure and upside, the partner network points to licensing-driven upside, geographic concentration in Greater China, and a pivot toward platform collaborations (imaging and ADC payloads). Learn more about partner intelligence and commercial exposure at https://nullexposure.com/.

How Lisata’s partner strategy funds the science

Lisata’s business model is built on a classic biotech commercialization trade: retain IP while outsourcing expensive development and commercialization risk to better-capitalized partners. Key monetization levers are upfront license fees, milestone and CVR contingent payments, and ongoing supply agreements for certepetide. Contracting posture is predominantly licensing (exclusive and nonexclusive), and partnerships span both therapeutics (ADCs, combination oncology regimens) and diagnostics (imaging). These characteristics imply:

  • Contracting posture: Licensing-first, with a mix of exclusive and nonexclusive grants that transfer development cost and execution risk to licensees.
  • Concentration: A material historic focus on Greater China via an exclusive license that had been assigned to Qilu, creating regional concentration risk.
  • Criticality and maturity: Certepetide is the company’s core product; partners are in early clinical or preclinical programs, so revenue is front-loaded and contingent on clinical progress.
  • Revenue recognition posture: Evidence of one-time license revenue recognition (a $1.0M license recognized in 2024) signals a pattern of monetizing IP via upfront fees rather than recurring product sales.

For tailored mapping of counterparties and exposure, see https://nullexposure.com/.

Relationship-by-relationship: what each partner does and why it matters

Qilu Pharmaceutical / Qilu Pharmaceutical Co., Ltd.

Qilu held an exclusive Greater China license to develop and commercialize certepetide and ran a parallel development program combining certepetide with gemcitabine and nab‑paclitaxel for metastatic pancreatic cancer; that license was mutually terminated in January 2026, and Lisata disclosed potential CVR considerations tied to rights reversion. (Source: Globenewswire Jan 27, 2026; Lisata Q3 2025 filings and releases FY2025–FY2026.)

Kuva Labs, Inc.

Kuva licensed certepetide in November 2024 to use as a targeting agent with its NanoMark™ MR imaging platform, taking responsibility for R&D and commercialization of the imaging product while Lisata supplies the peptide; Lisata recognized $1.0M of license revenue related to the agreement. Kuva later entered a binding acquisition term sheet to acquire Lisata for $4.00 per share with two non‑tradeable CVRs tied to reversion and NDA milestones. (Source: Globenewswire Dec 3, 2024; Globenewswire Jan 21, 2026; Lisata FY2024–FY2026 disclosures.)

Catalent, Inc. (CTLT)

Lisata granted Catalent a nonexclusive global license to evaluate certepetide and analogs as SMARTag® ADC payloads, positioning Catalent to integrate the peptide into ADC development across its Enhanced Conjugates pipeline; Catalent has reported positive preclinical data from these combinations. This is a material validation of certepetide as a non‑cytotoxic ADC payload. (Source: Globenewswire Oct 8, 2025; Nov 4, 2025; Lisata earnings call Q3 2025.)

GATC Health Corp

Lisata entered a strategic collaboration with GATC Health to use AI tools to de‑risk and accelerate drug development, with Lisata named as an operational development partner for GATC’s programs. This expands Lisata’s role beyond IP licensor into operational collaborator on development projects. (Source: Globenewswire Mar 5, 2025.)

Halper Sadeh LLC (investor-rights law firm)

Halper Sadeh LLC publicly announced an investigation into whether the proposed sale of Lisata to Kuva for $4.00 per share (plus CVRs) is fair to LSTA shareholders, signaling potential shareholder litigation or proxy friction that could affect deal timing or terms. (Source: AI Journ / Halper Sadeh notice, FY2026 reporting.)

What these relationships imply for investors: concentration, criticality and timing

Lisata’s partner map is IP‑centric and license-heavy, with a clear split between therapeutics (Catalent, Qilu historically) and diagnostics/imaging (Kuva). Several company-level constraints emerge from public disclosures:

  • Licensing is the dominant contract type, with both exclusive and nonexclusive deals used to monetize certepetide and transfer development cost (company signal from licensing evidence).
  • Regional concentration in APAC existed historically due to the Greater China license arrangement, creating execution and reversion risk when rights revert to Lisata (company-level signal supported by contract geography references).
  • North American exposure is material through Kuva (US-based partner) and Catalent (global CDMO partner), creating dual‑region commercialization pathways that reduce single‑market reliance (company-level signal).
  • Relationship maturity is early-stage but active, with preclinical/Phase 2 work and license consideration already recognized as revenue—this means short‑term revenue is dependent on discrete events (upfront fees, CVR triggers) rather than stable product sales.

Investment implications and risks to watch

  • Upside: Successful advancement of partners’ programs (ADC integration at Catalent, imaging validation at Kuva) could unlock milestone and CVR payments and increase the value of the peptide supply franchise.
  • Downside: Reliance on a small number of licensing transactions and the termination/reversion of regional deals (Qilu) concentrates execution risk; investor litigation or acquisition disputes (Halper Sadeh inquiry) can compress deal value or delay consideration.
  • Timing: Much of the economic value is contingent—CVRs, milestone payments, and reversion timing—so liquidity events are binary and event-driven.

If you want a deeper counterparty exposure report and a timeline of milestone triggers, visit https://nullexposure.com/ for subscription options and custom alerts.

Bottom line

Lisata’s model is IP monetization through licensing and supply, validated by blue‑chip partners (Catalent) and strategic imaging players (Kuva), with a notable historical concentration in Greater China that has recently been unwound. Value realization for shareholders hinges on partner execution, milestone triggers and the resolution of the proposed Kuva acquisition. For investors who need granular partner tracking and real‑time alerting on milestones or legal developments, learn about our coverage at https://nullexposure.com/.